Megha Rani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Megha Rani has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Anjna Rani
Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, 201306, India
2 shared publications - Rakhi Mishra
Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida,201306, India
2 shared publications - Rupa Mazumder
Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India
2 shared publications
Latest Publications
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Patents on Nanotechnology
- Vol. 20, 1-18
Advancements in Nanoparticle-based Treatment Approaches for Ocular Inflammation
Nanoparticles are small particles, typically 1-100 nm in size, designed as adaptable drug carriers to improve bioavailability, facilitate targeted delivery, and enable controlled release across biological barriers. Ocular inflammation, encompassing vision-threatening conditions such as uveitis, scleritis, and other inflammatory eye diseases, poses significant therapeutic challenges due to both static and dynamic barriers (including the corneal epithelium, tear film, and the blood-retinal barrier). The article comprehensively examines recent developments in nanoparticle-based drug delivery systems designed for ocular therapy, such as polymeric nanoparticles and dendrimers, inorganic nanoparticles, lipid-based systems, and novel platforms like microneedle patches and drugeluting implants. As demonstrated by in vitro models (such as porcine cornea penetration), in vivo animal studies (like rat uveitis models), patents, and developing clinical trials for non-infectious uveitis. These nanotechnologies overcome present limitations through superior targeting to anterior and posterior segments, prolonged residence time, controlled release, reduced toxicity, and also add some of the benefits like antioxidant, anti-inflammatory, and antimicrobial effects that depend on the nanoparticle type. It helps to overcome the poor bioavailability, NSAID-related side effects, and frequent dosing problems of conventional corticosteroids. However, regulatory barriers, scalability, and safety remain very important challenges for clinical translation. This review highlights how nanoparticle- based systems improve ocular bioavailability, reduce dosing frequency in inflammatory eye diseases, and prolong drug residence time, while also identifying key translational challenges related to regulation, scalability, and safety. Several formulations achieved multi-fold increases for days to weeks.
- 6 October 2026
- Published by Bentham Science Publishers Ltd. in Recent Patents on Nanotechnology
- Vol. 20, 1-18
Advancements in Nanoparticle-based Treatment Approaches for Ocular Inflammation
Nanoparticles are small particles, typically 1-100 nm in size, designed as adaptable drug carriers to improve bioavailability, facilitate targeted delivery, and enable controlled release across biological barriers. Ocular inflammation, encompassing vision-threatening conditions such as uveitis, scleritis, and other inflammatory eye diseases, poses significant therapeutic challenges due to both static and dynamic barriers (including the corneal epithelium, tear film, and the blood-retinal barrier). The article comprehensively examines recent developments in nanoparticle-based drug delivery systems designed for ocular therapy, such as polymeric nanoparticles and dendrimers, inorganic nanoparticles, lipid-based systems, and novel platforms like microneedle patches and drugeluting implants. As demonstrated by in vitro models (such as porcine cornea penetration), in vivo animal studies (like rat uveitis models), patents, and developing clinical trials for non-infectious uveitis. These nanotechnologies overcome present limitations through superior targeting to anterior and posterior segments, prolonged residence time, controlled release, reduced toxicity, and also add some of the benefits like antioxidant, anti-inflammatory, and antimicrobial effects that depend on the nanoparticle type. It helps to overcome the poor bioavailability, NSAID-related side effects, and frequent dosing problems of conventional corticosteroids. However, regulatory barriers, scalability, and safety remain very important challenges for clinical translation. This review highlights how nanoparticle- based systems improve ocular bioavailability, reduce dosing frequency in inflammatory eye diseases, and prolong drug residence time, while also identifying key translational challenges related to regulation, scalability, and safety. Several formulations achieved multi-fold increases for days to weeks.
- Open Access
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1695-1706
Fabrication of Curcumin-loaded Olaminosomes for Intracorneal Permeation Enhancement
Background: Curcumin, a polyphenolic compound obtained from Curcuma longa, demonstrates potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it a promising candidate for treating ocular inflammatory conditions. However, it faces significant challenges, including low bioavailability, rapid metabolic degradation, poor aqueous solubility, and inadequate corneal penetration. Aim: To formulate and optimise drug-loaded olaminosomes encapsulating Curcumin for enhanced ocular delivery. Methods: Preformulation studies were conducted, including solubility analysis in various solvents and drug excipient compatibility studies using Fourier-Transform Infrared Spectroscopy (FTIR). Olaminosomes, a novel nanovesicular carrier, were prepared using the ethanol injection method, incorporating octadecyl amine, span 80, and oleic acid as lipid, nonionic surfactant, and edge activator to enhance drug entrapment and corneal penetration. Results: The formulation exhibited a vesicle size of 430 nm, a polydispersity index (PDI) of 0.41, an entrapment efficiency of 29.6%, and ex vivo corneal permeation of 40% Curcumin and 60% olaminosomes over 2 hours. Conclusion: These findings underscore the potential of olaminosomes as a promising nanovesicular platform for sustained and targeted ocular drug delivery. Major Findings: Curcumin-loaded olaminosomes were successfully developed with a vesicle size of 430 nm, PDI of 0.41, and entrapment efficiency of 29.6%. The formulation significantly enhanced ex vivo corneal permeation (60%) compared to free Curcumin (40%).
- 30 June 2026
- Published by Informatics Publishing Limited in Journal of Natural Remedies
- p. 1695-1706
Open AccessFabrication of Curcumin-loaded Olaminosomes for Intracorneal Permeation Enhancement
Background: Curcumin, a polyphenolic compound obtained from Curcuma longa, demonstrates potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it a promising candidate for treating ocular inflammatory conditions. However, it faces significant challenges, including low bioavailability, rapid metabolic degradation, poor aqueous solubility, and inadequate corneal penetration. Aim: To formulate and optimise drug-loaded olaminosomes encapsulating Curcumin for enhanced ocular delivery. Methods: Preformulation studies were conducted, including solubility analysis in various solvents and drug excipient compatibility studies using Fourier-Transform Infrared Spectroscopy (FTIR). Olaminosomes, a novel nanovesicular carrier, were prepared using the ethanol injection method, incorporating octadecyl amine, span 80, and oleic acid as lipid, nonionic surfactant, and edge activator to enhance drug entrapment and corneal penetration. Results: The formulation exhibited a vesicle size of 430 nm, a polydispersity index (PDI) of 0.41, an entrapment efficiency of 29.6%, and ex vivo corneal permeation of 40% Curcumin and 60% olaminosomes over 2 hours. Conclusion: These findings underscore the potential of olaminosomes as a promising nanovesicular platform for sustained and targeted ocular drug delivery. Major Findings: Curcumin-loaded olaminosomes were successfully developed with a vesicle size of 430 nm, PDI of 0.41, and entrapment efficiency of 29.6%. The formulation significantly enhanced ex vivo corneal permeation (60%) compared to free Curcumin (40%).